These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 18413014

  • 1. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
    Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.
    Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L, Rémy V, Oyee J, Largeron N.
    Pharmacoeconomics; 2009 May; 27(3):231-45. PubMed ID: 19354343
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.
    Int J Technol Assess Health Care; 2008 May; 24(1):10-9. PubMed ID: 18218164
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH.
    Asian Pac J Cancer Prev; 2008 May; 9(3):459-66. PubMed ID: 18990021
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.
    Value Health; 2012 May; 15(5):622-31. PubMed ID: 22867770
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
    Obradovic M, Mrhar A, Kos M.
    Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA, Lepetic A, Demarteau N.
    BMC Public Health; 2014 Nov 26; 14():1222. PubMed ID: 25424716
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.